Mirati Therapeutics

• Founded

  1 Jan 1995

Sources: ror.org

• A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

  Phase 2, Recruiting, 170 people, 17 Feb 2026

• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  Phase 3, Recruiting, 630 people, 13 Mar 2025

• Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

  Phase 1, Terminated, 6 people, 3 May 2023

• NCT05609578

  Phase 2, Active, not recruiting, 90 people, 8 Nov 2022

• NCT05178888

  Phase 1, Completed, 11 people, 5 Jan 2022

• NCT04887194

  Phase 1, Completed, 40 people, 14 May 2021

• NCT02664935

  Collaborator, Phase 2, Completed, 423 people, 27 Jan 2016

Sources: clinicaltrials.gov

• Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study

  Consulting or advice, 22 Sept 2026

• From screening to surveillance: integrated prevention of Helicobacter pylori-associated gastric cancer in the Asia-Pacific region

  Consulting or advice, 17 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov